Patent ID: 7041784
Filing Date: 2006-05-09
Classification: A61K,C07K

Abstract:
1. A pharmaceutical composition comprising a therapeutically effective amount of an AV peptoid in dosage form and a pharmaceutically acceptable carrier, wherein the peptoid comprises the amino acid sequence Ala-Val-Pro, is fewer than 10 residues in length, has a molecular weight less than 1000, and interacts with an inihibitor of Apoptosis protein (IAP) as measured by IAP binding, wherein: (a) the peptoid is 3 residues in length; (b) the peptoid comprises a carbon-carbon or acyl bond in place of a peptide bond; (c) the peptoid comprises an N-terminus and a C-terminus and peptidyl bonds, wherein one or more of the peptidyl [—C(O)NR—] linkages have been replaced by a non-peptidyl linkage selected from the group consisting of: a —CH (d) the peptoid comprises an N-terminus and a C-terminus and peptidyl bonds, wherein the C terminus is derivatized to —C(O)R (e) the peptoid comprises an N-terminus and a C-terminus and peptidyl bonds wherein: one or more of the —C(O)NH— linkage have been replaced by a linkage selected from the group consisting of a —CR (f) the peptoid further comprises an N-substituted glycine analog having the general formula I: X (g) the peptoid comprises a backbone modification selected from the group consisting of: N-alkylation, α-ester, thioamide, N-hydroxylation, β-ester, sulfonamide, sulfonamide-N, urea, and urethane.